We have constructed a panel of substitution mutants which aect one or more of the putative cdk target sites of the RB protein. We have examined the activity of these mutants relative to wild-type RB by both a transcriptional repression assay and by measuring growth suppression in vitro. We ®nd that some phosphorylation site mutants of pRB can repress E2 transcription more strongly than wild-type RB. These mutants are partially resistant to phosphorylation by cdks and can arrest tumor cells in G1 in vitro. Our results indicate a functional correlation between the ability to repress E2F-dependent transcription and the ability to suppress tumor cell growth in vitro. In addition, we describe two classes of RB mutants: N-terminal truncated p56
Introduction RB, the retinoblastoma tumor suppressor gene product, is a key regulator of cell cycle control (for a review, see Weinberg, 1995) . Mutational inactivation of the RB gene has been found in a variety of human cancers. Restoration of RB gene expression to a variety of human tumor cell types results in growth suppression and reduced tumorigenicity (Bookstein et al., 1990; Goodrich et al., 1992; Huang et al., 1988; Kratzke et al., 1993; Ookawa et al., 1993; Takahashi et al., 1991; Wang et al., 1993) . The 110 kdalton RB gene product, pRB, contains several distinct functional domains. The N-terminus (amino acid 1-378) appears to be important for tethering to nuclear matrix and binding to RB-associated proteins (Inoue et al., 1995) . The C-terminal portion of pRB contains two domains, A and B that form a functional pocket. An intact pocket is required for binding to oncoproteins of several DNA tumor viruses: adenovirus e1A, SV-40 large T-antigen and HPV E7. A Cterminal fragment of RB, termed p56 RB (amino acids 379 ± 928) is sucient to mediate E2F binding and growth suppression in a Saos-2 (Goodrich et al., 1991; Huang et al., 1992; Qin et al., 1992 Qin et al., , 1995 .
RB is a nuclear phosphoprotein (Lee et al., 1987) and is phosphorylated at both serine and threonine residues (Buchkovich et al., 1989; Ludlow et al., 1989; Shew et al., 1989) . Phosphorylation of pRB occurs in a cell-cycle dependent manner (Buchkovich et al., 1989; Chen et al., 1989; DeCaprio et al., 1989) and presumably down regulates RB's activity by disrupting E2F-RB complexes . RB is found in a hypophosphorylated form during G1 and is progressively phosphorylated during G1, presumably by cdk4/cyclin D complexes (Akiyama et al., 1992; Dowdy et al., 1993; Ewen et al., 1993; Hinds et al., 1992; Horton et al., 1995; Kato et al., 1993) . RB is dephosphorylated during mid-M phase and the type 1 protein phosphatase has been implicated in this process (Alberts et al., 1993; Durfee et al., 1993; Ludlow et al., 1993) .
Several lines of evidence, both direct and indirect, suggest that phosphorylation of pRB alters its activity. First, the DNA tumor virus oncoproteins complex nearly exclusively with hypophosphorylated pRB (DeCaprio et al., 1988; Dyson et al., 1989; Whyte et al., 1988) . Second, hyperphosphorylated pRB and nonfunctional mutants of pRB are weakly associated to nuclear components, whereas hypophosphorylated pRB is tightly associated in the nucleus . Third, phosphorylation of pRB, mediated by coexpression of cyclins, cdks or both results in loss of RB's growth suppression potential and ability to bind E2F (Dowdy et al., 1993; Hinds et al., 1992; Horton et al., 1995; Kato et al., 1993) . Fourth, phorbol ester induced RB dephosphorylation is associated with growth arrest and dierentiation in myeloid cells (Chan et al., 1989) . Finally, when compared to wild-type pRB, a nonphosphorylatable mutant of murine RB exhibited a markedly increased ability to repress transcription of the adenovirus E2a promoter (Hamel et al., 1992) .
The state of phosphorylation (and hence activity) of pRB is modulated by external stimuli. For example, cells made quiescent by serum starvation contain exclusively hypophosphorylated RB (Mihara et al., 1989) . Some cytokines such as TGF-b prevent phosphorylation of pRB, probably by acting through cdk-inhibitors such as p15 ink4b (MTS-2) (Alexandrow and Moses, 1995) . The eect of reintroduced pRB on the growth rate and tumorigenicity of some RB neg tumor lines depends on external factors such as serum and presence of extracellular matrix. For example, RB does not aect growth of 5637 bladder carcinoma cells in culture at 10% serum, but does so at 3% serum (Takahashi et al., 1991) . RB-mediated tumor suppres-sion can be blocked by treatment of tumor cells with extracellular matrix (matrigel) (Kratzke et al., 1993) . This suggests that the ability of RB to regulate cell cycle control is controlled, at least in part, by external stimuli.
We hypothesized that pRB probably does not function in 5637 cells in 10% serum due to its inactivation by phosphorylation. In the present study we demonstrate that several classes of human RB can arrest 5637 cells in G1 under conditions in which wild type RB does not. A nonphosphorylatable mutant RB110-788/807/811, a C-terminal substitution mutant (p5) and an N-terminal truncation mutant (RB56) all have greater activity than wild-type pRB. The ability of these mutants to arrest 5637 cells in G1 correlates with their ability to repress transcription from the adenovirus E2a promoter. These results suggest that there are multiple ways to create a more active RB molecule.
Results

In vitro phosphorylation of full length and truncated retinoblastoma protein
The retinoblastoma protein is 928 amino acids in length and contains multiple putative cdk phosphorylation sites, several of which are known to be phosphorylated in vitro (Lees et al., 1991) (Figure 1 ). We initially chose to examine the eect of altering putative cdk sites to make them phosphorylation resistant. This method has been used successfully by others to produce a more active variant of murine RB (Hamel et al., 1992) . To make similar variants in the context of the human RB gene, we replaced the serine residues of p110 RB at positions 608, 612, 788, 807 and 811 with alanine in the indicated mutants ( Figure 1a ). RB110-p5 contains multiple substitutions in the indicated region as described in the methods. Similar serine to alanine substitution mutants were constructed in the context of p56 RB , a previously described Nterminally truncated form of pRB (Goodrich et al., 1991) (Figure 1b) .
To determine the extent of pRB phosphorylation, we incubated puri®ed p110 RB or p56 RB with anti-cyclin A,B,D3 or E complexes produced multiple bands of decreased mobility, which presumably are hyperphosphorylated species of pRB. At least four species of p110 RB and p56 RB can be resolved. Cyclin A complexes produced the greatest amount of hyperphorphorylated pRB, whereas cyclin D3 complexes produced the least. Other D-type cyclins (for example, cyclin D1) were not included in this study due to previously published reports that cyclin D1 does not phosphorylate pRB in vivo (Dowdy et al., 1993; Hinds et al., 1992) . The cell line MOLT-4 contains relatively high levels of active cdk/cyclins and a high proportion of its pRB is in the hyperphosphorylated form . Incubation of p56 RB with a partially puri®ed MOLT-4 lysate also resulted in production of multiple hyperphosphorylated species of pRB. These results indicate that both p110 RB and p56 RB can be hyperphosphorylated in vitro.
In vitro phosphorylation of p56 RB alters its activity
The in vitro hyperphosphorylation of pRB is not meaningful unless it produces functional changes associated with known activities of pRB. We therefore assessed the ability of hyperphosphorylated RB to arrest cells in G1. In vitro phosphorylation of p56 RB by immune complexes of cyclin A or E or partially puri®ed MOLT-4 lysates greatly decreased the ability of microinjected p56 RB to cause G1 arrest in Saos-2 (Table 1) . The fact that the activity of the in vitro phosphorylated pp56 RB was not completely eliminated most likely indicates our inability to achieve complete in vitro phosphorylation of 100% of the p56 RB .
Cyclin/cdk mediated phosphorylation of wild-type and engineered pRB
An alternate method to producing hyperphosphorylated species of pRB is to constitutively express cyclins, such as cyclin E, in vivo. Hinds et al., (1992) reported that cyclin E coexpression caused hyperphosphorylaa b Figure 1 Phosphorylation mutants of pRB. The RB protein is 928 amino acids in length. The small pocket domain contains two domains (shown in gray) (a) and (b) separated by a spacer region and extends from amino acids 379 ± 779. The large pocket required for full activity extends from amino acid 379 ± 928. Putative cyclin-dependent kinase sites occur throughout the molecule and have the consensus B(S/T)PXB, where b is a basic residue and X is a polar residue. Sites indicated by a black marker are known to be phosphorylated in vivo. Most of the remaining sites are probably phosphorylated as well. Substitution point mutants were made in the context of both full length (RB110) (a) and N-terminal truncated (RB56) RB (b). In each case, the indicated serine residues were replaced with alanine. p5 mutant: The p5 mutant contains multiple substitutions between amino acids 881 ± 889 (indicated by the *) as described in the Materials and methods. The properties, physical and biological characterization of p5 will be described elsewhere (B Driscoll and YK Fung submitted)
Engineered mutants of RB D Antelman et al tion of RB and the subsequent inability of ppRB to arrest Saos-2 cells. The relative levels of endogenous cdks and cyclins, which in¯uence the extent of RB phosphorylation, can vary in dierent cell lines. To examine the eects of cyclin E coexpression on wildtype p110 RB and p56 RB phosphorylation, we cotransfected the RB plasmids (described in Figure 1 ) with varying amounts of cyclin E (Figure 3a and b) . In 5637 cells, in the absence of exogenous cyclin E, both p110 RB and p56 RB migrate as single species. Cyclin E coexpression resulted in production of multiple species of hyperphosphorylated pRB. At near equimolar pCMV-RB110 and pCMV-cyclin E plasmid concentrations three to four species of hyperphosphorylated RB were produced. Higher cyclin E: RB ratios resulted in less pRB production overall and did not produce additional hyperphosphorylated species. pCMVRB56+pCMV-cyclin E cotransfections produced a similar pattern of hyperphosphorylation, although it was necessary to use higher molar ratios of RB56 : cyclin E plasmid to obtain ecient p56 RB phosphorylation.
We also examined the ability of various cyclins and cyclin-dependent kinases (cdks) to mediate phosphorylation of p110 RB in 5637 cells (Figure 3c ). Cyclin D1 or cdk4 produced little RB phosphorylation when utilized individually, but hyperphosphorylated species of pRB were produced with a combination of the two (Figure 3c , lanes 4 ± 6). In contrast, cyclin E or cdk2 could promote ecient pRB phosphorylation when used individually or together (Figure 3c , lanes 7 ± 9). The combination of cyclin E and cdk2 was particularly eective and resulted in production of four hyperphosphorylated pRB species.
Because cyclin E mediated phosphorylation was particularly eective, we further examined the phosphorylation status of full length, wild-type p110 RB and p110 RB mutants in the 5637 cell line (Figure 3d ). In the absence of cyclin E, 5637 cells harvested 48 h post transfection contained nearly exclusively hypophosphorylated RB (Figure 3d , lane 6). However, in 5637 cells cotransfected with cyclin E and RB variants the phosphorylation state of RB depended upon the RB variant used. As shown previously, in the presence of coexpressed cyclin E, wild-type, full length p110 RB exists in hypophosphorylated and at least three hyperphosphorylated forms (lane 7). As expected, the nonfunctional mutant RB110-H209 also was not phosphorylated. In the presence of exogenous cyclin E, the variants RB110-608/612, RB110-788/807/811 and RB110-p5 occur as a mixture of hypophosphorylated and one to two phosphorylated forms. The preferential pattern of hyperphosphorylation of wildtype p110 RB was seen reproducibly over the course of several transfection studies in 5637 (data not shown). These results suggest that the speci®c mutations in RB110-608/612, RB110-788/807/811 and the RB110-p5 result in changes in their cyclin E-dependent hyperphosphorylation pattern, as observed by SDS-polyacrylamide gel electrophoresis.
RB phosphorylation site mutants are more ecient at repressing E2F-dependent transcription
The ability of pRB to regulate cell cycle progression is dependent upon its ability to interact with the transcription factor E2F-1 and to subsequently repress transcription Hiebert et al., 1992) . In the absence of functional RB, the adenovirus E2 promoter is actively transcribed (Weintraub et al., 1992) . Restoration of RB gene expression results in transcriptional repression of E2 and the extent of repression depends on both the intracellular level and the activity of pRB. To assess the ability of our pRB variants to repress E2 transcription, we cotransfected each RB variant and the Ad-E2-CAT reporter construct p-E2-CAT into C33A, a cell line which contains a nonfunctional, mutant form of pRB (Schener et al., 1991) (Figure 4a ). Because RBmediated repression of the E2 promoter does not cause G1 arrest in C33A (Zhu et al., 1994) one can accurately measure the ability of RB to repress transcription without the interfering or secondary eects of cell cycle arrest. As previously reported (Weintraub et al., 1992) , introduction of an E2-CAT reporter construct into C33A resulted in high levels of CAT activity. Introduction of wild-type, full length pRB (RB110-WT) resulted in a twofold decrease in E2 transcription. RB110-608/612, which lacks two of the putative cdk phosphorylation sites, repressed transcription to the same extent as RB110-WT. In contrast, the triple site mutant RB110-788/807/811 repressed tran- scription approximately ®vefold. RB110-p5, which contains multiple substitutions in the region containing amino acids 881 ± 889 (as described in methods) also was a more eective transcriptional repressor than RB110-WT. RB56-WT (amino acids 379 ± 928) repressed E2 transcription approximately tenfold and was the most ecient RB variant in our assay. Transcriptional repression of E2 by RB requires an intact RB pocket domain and most of the C-terminus ). Expression of a described nonfunctional RB mutant, C706F in either full length (RB110-H209) or N-terminal truncated (RB56-H209) forms did not result in transcriptional repression of E2. The eect of both wild-type pRB and the pRB variants on transcription is speci®c for the promoters containing the E2F consensus DNA binding sites. Transcriptional repression only occurred when functional E2F DNA binding sites were present and functioned in both the Ad-E2 promoter as well as a previously described (Weintraub et al., 1992) synthetic E2 promoter (data not shown). Expression of functional RB did not aect the transcriptional activity of SV-40 early promoter-CAT constructs in C33A (data not shown). . The plasmid pCMV-RB110 was cotransfected with the indicated ratios of pCMV-cyclin E plasmid into 5637 cells and cell extracts were prepared. Extracts were resolved by SDS ± polyacrylamide gel electrophoresis and probed with 3C8 monoclonal antibody as described in the methods. Slower mobility isoforms represent hyperphosphorylated species of RB protein. The MOLT-4 lysate contains hyperphosphorylated RB. (b) Cyclin E coexpression drives hyperphosphorylation of p56 RB . The plasmid pCMV-RB56 was cotransfected with the indicated ratios of pCMV-cyclin E plasmid into 5637 cells and cell extracts were prepared. Extracts were resolved by SDS-polyacrylamide gel electrophoresis and probed with 3C8 monoclonal antibody as described in the Materials and methods. The left most lane contains p56 RB puri®ed from E. coli as described in the Materials and methods. (c) Phosphorylation of pRB with combinations of cdk and cyclin. The plasmid pCMV-RB110 was cotransfected with the indicated pCMV-cyclin or pCMV-cdk plasmid or combination thereof. RB proteins were analysed as described above. The migration of p110 RB puri®ed from E. coli and MOLT-4 lysate containing hyperphosphorylated pRB are indicated in lanes 1 and 2. (d) Cyclin E mediated hyperphosphorylation of wild type and mutant p110 RB in 5637 bladder carcinoma cells. The indicated RB cdk site mutants were transfected with (+) or without (7) pCMV-cyclin E into 5637 cells as described in the Materials and methods. Extracts were prepared from 5637 cells and immunoblotted as described in the Materials and methods. The migration of hyperphosphorylated pp110 RB in MOLT-4 is indicated in lane 1
The greater activity of RB56 in our CAT reporter assay suggested that p56RB is functionally distinct from full length pRB. The ability of p110 RB to repress Ad-E2 transcription was augmented by either of two means: directly altering cdk phosphorylation sites or by introducing alterations in the p5 region of the protein (Figure 4a ). In contrast, we were unable to augment the activity of p56 RB by introducing similar sequence changes. Introduction of the serine4 alanine alterations at position 788, 807 and 811 or at positions 608, 612, 788, 807, 811 (RB56-5s) did not result in further promoter repression. Similarly, the p5 substitution mutant (RB56-p5) had the same activity as RB56.
While the cell line C33A is useful for promoter repression studies, the presence of an endogenous mutant form of pRB made determination of the relative expression levels of RB110 variants dicult. We therefore examined the ability of the RB variants to repress E2a transcription in 5637, an RB neg cell line Takahashi et al., 1991) . The data of Figure 4b demonstrate that RB110 can eciently repress E2F-dependent transcription in 5637 cells. In agreement with our earlier observations in C33A, RB110-788/807/811, RB110-p5 and RB56 all repressed transcription more eciently than RB110, although the dierences between these mutants and RB110 is less pronounced. Interestingly, in the 5637 cell line, truncated, nonfunctional mutant RB (RB56-H209) repressed transcription threefold, whereas the same mutant in the context of full length RB (RB110-H209) did not. This observation suggests that under some circumstances RB56-H209 may have limited activity and has such been noted in both promoter repression and growth suppression assays by others (Arroyo and Raychaudhuri, 1992; Qin et al., 1992) .
Dose-response studies on RB and RB mutants
The promoter repression assays of RB variants performed in C33A and 5637 employed a single concentration of RB plasmid, which may have been close to saturation. While a ®xed, single concentration of RB plasmid may show activity dierences between RB variants, a dose response assay produces more meaningful results and has been employed for the previously described RB cdk mutant Dp34RB (Hamel et al., 1992) . We therefore chose to more carefully analyse the ability of RB variants to repress E2F-dependent transcription in both 5637 and C33A. Figure 5a compares the ability of RB110-WT, RB110-788/807/811 and RB110-p5 to repress transcription of the Ad-E2 promoter at varying levels of RB expression. At high amounts of RB plasmid (1 mg) there are only slight dierences in transcriptional repression between the mutants. However at lower amounts of DNA, both RB110-788/807/811 and RB110-p5 repressed transcription more eciently than RB-110 (75% decrease vs 25% decrease at 0.1 mg DNA). The concentration dependence of transcriptional repression revealed an even greater dierence in RB110 and RB56 (Figure 5b ). Almost 50 times as much RB110 DNA is required to achieve the same transcriptional repression as RB56 (0.5 mg vs 0.01 mg). The dose-dependent promoter repression observed for RB110-608/612 did not dier appreciably from that of wild-type RB (Figure 5c ) in agreement with our earlier observations (Figure 4a and b) . The dierences in transcriptional repression seen for the RB mutants is not simply due to higher expression levels of the mutant forms of pRB (Figure 5d , e, f). Similar results were obtained if RB plasmids were titrated against p-E2-CAT in C33A (data not shown).
Transcriptional repression and growth suppression by RB mutants are linked
The ability of RB mutants to repress E2 transcription also correlated with their ability to arrest 5637 cells in G1 (Figure 6 ). Expression of full length, wild-type (Figure 6c ) caused only a slight increase in % G1 and decrease in % S-phase when compared to control cells expressing mutant, nonfunctional RB (Figure 6b ). In contrast, RB variants RB110-788/807/ 811, RB110-p5 and RB56 (Figure 6d , e, g, respectively) caused an ecient G1 arrest. In agreement with the promoter repression data, RB56-5s arrested cells in an identical manner to RB56 (Figure 6h) . A mutant form of RB56 (Figure 6f ) failed to cause G1 arrest. To demonstrate that 5637 cells can indeed be arrested by full length, wild-type RB, we expressed higher amounts of p110 RB by using a modi®ed expression vector. In both Saos-2 and 5637 cells the modi®ed vector pCTM-RB expresses approximately ®ve times more pRB than the pCMV-RB vector initially used in FACS analysis (data not shown). pCTM-RB caused a substantial G1 arrest when compared to pCMV-RB or control treated 5637 cells (Figure 6i ). These results indicate that both the expression level and activity of the RB variant dictate the extent of growth inhibition of cultured cells. 
Cyclin E blocks the eects of pRB
De®ned activities of pRB, such as promoter repression and the ability to cause growth arrest can be altered or eliminated if the phosphorylation state of pRB is in¯uenced by constitutive expression of cdk/cyclin complexes (Dowdy et al., 1993; Hinds et al., 1992; Horton et al., 1995) . Because cyclin E caused ecient phosphorylation of pRB in vitro (Figure 2 ) and in vivo (Figure 3 ) we sought to determine if coexpression of cyclin E would alter the activity of RB in vivo. We therefore contransfected C33A with E2-CAT reporter vector and RB variants in the absence and presence of cyclin E and measured the extent of promoter repression as earlier (Figure 7 ). In the absence of RB, expression of cyclin E had a slight stimulatory eect on the E2 promoter. Coexpression of cyclin E with RB110 completely blocked its ability to repress E2 transcription. Coexpression of cyclin E with RB110-608/612 produced a similar result. In contrast, cyclin E coexpression only partially blocked the ability of RB110-788/807/811 or RB56 to repress E2 transcription. These results suggest that the RB mutants behave dierently under conditions favoring RB hyperphosphorylation.
Discussion
Regulation of RB activity by phosphorylation is a complex process. Several kinases have been implicated in RB phosphorylation, such as p34-cdc2 (Hu et al., 1992; Kitagawa et al., 1995; Lees et al., 1991; Lin et al., 1991) and cdk2 (Akiyama et al., 1992) . More recently, cdk4 and D-type cyclins have been suggested as the biologically relevant RB kinases in vivo (Dowdy et al., 1993; Ewen et al., 1993; Horton et al., 1995; Suzuki-Takahashi et al., 1995) . Putative cdc2 or cdk sites with the consensus B-S/T-P-X-B (where B=basic amino acid, and X is a polar residue) occur throughout the RB molecule. At present, ®ve of these sites (S249, T252, T373, S807 and S811) are known to be phosphorylated in vivo (Lees et al., 1991) . These results were derived from phosphopeptide mapping of pRB extracted from the myeloid leukemia cell line ML-1. Because many subsequent studies typically utilized RB (7/7) cell lines, such as Saos-2, it is unclear whether the phosphorylation pattern of pRB seen in ML-1 occurs universally.
While phosphopeptide mapping yields useful information about which cdk sites in RB are phosphorylated, it does not yield information about the functional signi®cance of phosphorylation at individual sites. We therefore chose to create phosphorylation resistant mutants of pRB, based on the putative cdc2 phosphorylation sites in RB. Such an approach has been used successfully by others (Hamel et al., 1992) to create a phosphorylation-resistant murine RB. Because human RB is better suited for human gene therapy, our study focused on creating more potent variants of the human retinoblastoma protein.
The dierential migration of hyperphosphorylated and hypophosphorylated pRB on SDS-polyacrylamide gels was initally reported by Ludlow et al., (1989) and was con®rmed in two subsequent studies (Buchkovich et al., 1989; DeCaprio et al., 1989) . Thus it is generally accepted that slower migrating forms of pRB on SDSpolyacrylamide gels represent hyperphosphorylated species of pRB. We used this approach to determine the extent of phosphorylation of both wild-type and mutant forms RB used in our studies.
Initially, we chose to perform in vitro phosphorylation of pRB with cdk/cyclin immunoprecipitates. Both p110 RB and truncated p56 RB served as ecient substrates for cyclin A, B, D2, D3 and E (Figure 2 ), although cyclin D3 was less eective. Dierences in phosphorylation eciency by various cyclins can be attributed to the relative eciency of immune complex formation or to the dierent levels of endogenous cyclins in cell extracts. As expected, RB phosphorylation caused loss of its known activities, i.e. phosphorylated RB failed to cause G1 arrest in Saos-2 cells (Table 1 ) and failed to bind to either T-antigen or E2F-1 (data not shown). These results correlate the loss of known activities of pRB with its hyperphosphorylation.
Because a known activity of RB is to interact with and repress transcription of E2F-dependent promoters, we initially ranked the activities of the RB mutants based on their ability to repress transcription of the adenovirus E2a promoter. Transcription of E2-CAT reporter constructs is highly repressed in RB + cell lines and highly activated in RB (7/7) cell lines (Weintraub et al., 1992) . In agreement with these observations, we found that transcription of p-E2-CAT was highly activated in C33A (Figure 4a ) and highly repressed in the RB + cell line A549 (data not shown). More important was the ®nding that three dierent classes of RB mutants yielded greater promoter repression than wild-type RB. These observations were made in two RB neg cell lines, the cervical carcinoma C33A and the bladder carcinoma 5637. A signi®cant ®nding of these studies was that N-terminal truncated p56 RB was much more ecient than full length pRB at repressing E2a transcription (Figure 4a, b and Figure 5b ). Given that p56 RB and p110 RB are expressed at roughly equal levels in our experiments (Figure 5e ), these results suggest that p56 RB potentiates a greater eect on E2F-RB transcriptional complexes. At this point, it is unclear if this occurs due to more ecient binding of p56 RB to E2F or slower release during complex dissociation that occurs as pRB is progressively phosphorylated. We also observed greater repression of E2a transcription with certain mutants of full-length pRB. At subsaturating concentrations of plasmid, RB110-788/807/811 and RB110-p5 both repressed transcription of E2a 3 ± 4-fold better than wild-type RB (Figure 5a ). RB110-608/612 had activity equal to that of wild-type RB, suggesting that the phosphorylation of these two serine residues is not biologically relevant (Figure 5c ). While the RB110-788/807/811 mutant's greater activity must occur through the elimination of serine residues that are normally phosphorylated, the mutations in RB110-p5 also result in gain of function. The substitution mutations in p5 occur in a region outside of the binding pocket and regions know to be important for E2F binding Qian et al., 1992) . In our assays, p5 behaved identically to RB110-788/807/811 (Figures 4, 5a and 6) suggesting some functional similarities. The properties and characterization of p5 will be fully described elsewhere (B Driscoll and Y Fung manuscript submitted).
Previous studies have linked the in vivo cyclinmediated hyperphosphorylation of RB with loss of its growth suppressive activity Hinds et al., 1992; Horton et al., 1995) . It is inferred that the loss of growth control occurs through loss of E2 promoter repression. Under similar conditions that favor hyperphosphorylation, we ®nd that RB56 and Figure 7 Cyclin E coexpression mediates RB phosphorylation and inactivation. The CAT reporter plasmid, pE2-CAT was cotransfected with the indicated RB expression plasmids either in the presence (+) or absence (7) of pCMV-cyclin E into C33A cervical carcinoma cells. Cell extracts were prepared and CAT activities were determined and normalized for transfection eciency as described in the Materials and methods
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D Antelman et al RB110-788/807/811 are still able to mediate promoter repression, whereas RB110 is not (Figure 7 ). Both RB110-788/807/811 and RB110-p5 exist in predominantly hypophosphorylated forms in cyclin E expressing cells, which under identical conditions contain more extensively hyperphosphorylated wild-type RB110 (Figure 3d ). While RB110-788/807/811 and RB110-p5 probably achieve greater activity through resistance to cdk-mediated phosphorylation, the means by which RB56 achieves its greater activity is less clear. Our experiments clearly show that hyperphosphorylation of p56 RB is possible both in vitro (Figure 2 ) and in vivo (Figure 3b) , although detailed phosphopeptide mapping of p56 RB has not been performed. Thus it is not possible to say whether p56 RB is phosphorylated at sites which govern the activity of p110 RB . More importantly, in vitro phosphorylation of p56 RB caused loss of its ability to arrest Saos-2 cells. It is plausible that in vivo phosphorylation p56 RB is of less consequence or that the N-terminus of pRB mediates pRB's inactivation by cyclin-dependent kinases. Introduction of the serine 788/807/811 mutations or p5 mutation, which enhanced the activity of RB110, did not augment the activity of RB56.
Our ®ndings that p56 RB is a more potent transcriptional repressor of E2F and can arrest cells in G1 more eciently than p110 RB did not come as a complete surprise. Two previously published reports suggest that N-terminal truncated RB has altered phosphorylation and activity. Hamel et al., (1990) reported that large Nterminal deletion mutants of murine pRB are poorly phosphorylated. Xu et al. (1994) reported that Nterminal truncated p94 RB has enhanced growth suppressive activity and reduced phosphorylation in 5637 when compared to full length p110 RB . In that study, 5637 cells were harvested 12 h post transfection and contained both hyperphosphorylated and hypophosphorylated p110 RB , but only hypophosphorylated p94 RB . In our studies of transfected 5637, we did not detect signi®cant hyperphosphorylation of p110 RB or p56 RB unless exogenous cyclin E was coexpressed (Figure 3 ). This dierence may be attributed to the time after transfection at which the cells were harvested (48 h vs 12 h in Xhu et al.) .
Our studies also show that RB mediated E2 promoter repression and growth suppression are correlative. RB mutants which were most active in the promoter repression assay were also the most ecient at arresting 5637 cells in G1. The almost complete cell cycle arrest seen in RB56 and RB110-p5 transfected 5637 cells (Figure 6 ) suggests that these RB mutants may be more potent in an in vivo tumor model. In fact, in 5637 complete G1 arrest and elimination of S-phase could not be achieved with wild type, full length pRB, even at higher expression levels. Xu et al., (1996) recently reported that p94 RB adenovirus has a greater antiproliferative eect than a p110 RB adenovirus in two in vivo orthotopic tumor models, H2009 and 5637. This result implies the potential use of N-terminal truncated RB as an alternative to wild-type RB for cancer gene therapy.
Phosphorylation resistant RB variants have proven utility in animal models of hyperproliferative disorders such as restenosis. The described murine RBDp34 mutant (Hamel et al., 1992) can inhibit smooth muscle cell proliferation in vitro and restenosis in vivo, although its activity was not compared to wild-type RB (Chang et al., 1995) . The ability of phosphorylation-resistant pRB to inhibit growth of cells containing seemingly normal pRB suggests that phosphorylation resistant RB can act in act in a dominant fashion. The greater activity of either phosphorylation resistant pRB or truncated pRB in numerous in vitro assays and in vivo systems warrants further examination of their suitability for treatment of cancer and hyperproliferative diseases.
Materials and methods
Protein puri®cation
p56
RB and p110 RB were puri®ed as described (Hensey et al., 1994) . Cyclin immune complexes were prepared by mixing whole cell lysates of MOLT-4 cells with speci®c anti-cyclin antibodies and protein A sepharose CL4-b (Pharmacia) for 1 h at 48C. Each immune complex reaction contained a lysate derived from *10 5 cells and a 1 : 1000 dilution of the appropriate antibody. p13 agarose-cdk complexes were similarly prepared by mixing MOLT-4 lysate with p13 agarose using the conditions described above. Cyclindependent kinase complexes were washed three tmes with PBS, 0.2% Nonidet P-40.
In vitro phosphorylation of pRB
For visualization of hyperphosphorylated pRB 50 ml kinase reactions each containing 50 mM Tris-acetate pH 7.4, 10 mM MgCl 2 , 1 mM DTT, 0.3 mM ATP, 0.25 mCi/mL [g-32 P]ATP and 0.5 mg of either p56 RB or p110 RB were incubated with immune cyclin complexes described above for 30 min at 378C, reaction products were resolved on 8% SDS-polyacrylamide gels and were subsequently analysed by phosphorimaging on a phosphorimager SF (Molecular Dynamics, Sunnyvale, CA). p56 RB for use in microinjection assays was phosphorylated as described above except that the [g-32 P]ATP was omitted.
Microinjection assay
Cyclin-dependent kinase immune complexes were removed by centrifugation and phosphorylated p56 RB was then microinjected into Saos-2 cells and a G1 arrest assay was performed as described (Goodrich et al., 1991) . BrdU was obtained from Amersham (Arlington Heights, IL).
Antibodies a-cyclin A and a-cyclin B antibodies were gifts from J Pines;a-cyclin D2 and a-cyclin D3 antibodies were provided by C Sherr.a-cylin E antibody was provided by Dr S Reed (Scripps, La Jolla, CA). a-RB 3C8 Mab was prepared as described (Wen et al., 1994) . Conjugated antibodies and a-BrDU were obtained from Amersham.
Plasmids pCMV-CD20 (Zhu et al., 1994) was generously provided by Dr Ed Harlow. Cyclin E cDNA was provided by Dr S Reed and was subcloned into pCMV, to create pCMVcyclin E. pCMV-cdk2, pCMV-cdk4 and pCMV-cyclin D1 were provided by Dr G Enders. pCMV-b-gal was obtained from Clontech (Palo Alto, CA).
Full length p110
RB expression plasmids were constructed as follows: The vector pA9-RB contains the AMV RNA4 5'-noncoding region fused to full length RB cDNA and has Engineered mutants of RB D Antelman et al been described . Individual serine ? alanine mutations were constructed by subcloning an EcoRI fragment of RB cDNA into M13mp18 and performing site directed mutagenesis as described (Kunkel, 1985) . Codon changes utilized were TCT ? GCT (608,612), AGC ? GCC (788), TCA ? GCA (807) and AGT ? GCT(811). The RB110-H209 mutant contains the change TGT (Cys) ? TTT (Phe) at position 706 as described . Appropriate fragments of the mutant RB genes were then subcloned back into the PA9-RB plasmid. The full length RB genes were then cloned as SacI/HindIII fragments into a pCMV expression vector to create pCMV-RB110. The plasmids pHbA-RB788/807/811 and pHbA-RB-p5 were obtained from Dr YK Fung. pCMV-RB110-788/807/811 and pCMV-RB110-p5 were created by excising the coding sequences of the respective RB genes of the pHbA parent plasmids with BamH1 followed by subcloning into a pCMV expression plasmid. Following subcloning into pCMV, all mutations were veri®ed by sequencing both strands using the Prizm dideoxy chain terminator method (Perkin Elmer). Sequencing reactions were analysed on an ABI 373A sequencer.
p56
RB plasmids pCMV-RB56 was constructed by PCR of pA9-RB with a 5' primer containing a SalI site (5'-GTCGACATGAACACTATC) and a 3' primer containing a HindIII site. The resulting PCR product was digested with HindIII and SalI and subcloned into pCMV. Mutants of RB56 were created by using the mutant pA9-RB clones described above as the PCR templates. pCMV-RB56-5s was constructed by subcloning a MluI ± HindIII fragment of pHbA-RB788/807/811 into pCMV-RB56-608/612. pCMV-RB56-p5 and pCMVRB56-3s were constructed by subcloning an MluI ± HindIII fragment of pHbA-RB-p5 into either pCMV-RB56 or pCMV-RB56-608/612, respectively.
p5 mutant p5 contains amino acid substitution mutations in RB as the following positions: 881 (gly ? ala), 883 (asp ? ala), 885 (ala ? val) and 889 (lys ? ile). The construction and properties of p5 will be fully described elsewhere (Driscoll and Fung, submitted).
Cell lines
All cell lines used in this study were obtained from American Type Culture Collection (Rockville, MD). Saos-2 were passaged in F12 : Dulbecco's modi®ed Eagle's medium (1 : 1) with 0.2 M glutamine and 15% fetal bovine serum. 5637 were passaged in RPMI 1640 (10% fetal bovine serum). C33A were passaged in minimum essential Eagle's medium with 10% fetal bovine serum. All cell lines were maintained in a humidi®ed-air/7% CO 2 incubator at 378C.
RB-cyclin/cdk cotransfections
5637 cells were seeded into each well of 6-well plates and allowed to adhere overnight. Transfections were performed with the lipofectin reagent (Gibco-BRL, Gaithersberg, MD) using a 3 : 1 ratio of lipid : DNA. For varying pCMV-RB110 or pCMV-RB56 : cyclin E stoichiometry, 1 mg of the RB plasmid was cotransfected with the appropriate amount of pCMV-cycE plasmid. The total amount of DNA transfected was kept constant by addition of pUC19 plasmid DNA to the transfection mixes. Transfections typically contained 3 ± 4 mg total plasmid DNA. Cotransfections of cyclin E, D1, D4, cdk2, cdk4 or combinations thereof contained 1.5 mg of pCMV-RB110 with 0.3 mg each of the appropriate cyclin or cdk expression plasmid. The total amount of plasmid DNA transfected was 3 mg and kept constant by addition of pUC19 DNA to the transfection mixes. Cotransfections of RB mutants and cyclin E in 5637 cells contained 1.5 mg of pCMV-RB expression plasmid and 0.5 mg pCMV-cycE. Cotransfection of RB mutant plasmids, E2-CAT reporter plasmids and cyclin E in C33A cells was performed using the conditions described for the transcriptional repression assay described below. Transfection mixes contained 5 mg pCMV-RB expression plasmid, 5 mg E2-CAT reporter plasmid, 2.5 mg of pCMV-cycE and 2.5 mg pCMVb-gal.
Transcriptional repression assay C33A: 250,000 C33A cells were seeded into each well of 6-well plates and allowed to adhere overnight.
Fixed plasmid concentrations 5 mg of each pCMV-RB vector cotransfected with 5 mg of the pE2-CAT reporter plasmid and 2.5 mg pCMV-b-gal per well into duplicate wells.
Plasmid titrations 0-10 mg of each pCMV-RB vector was cotransfected with 5 mg of the pE2-CAT reporter plasmid and 2.5 mg pCMV-b-gal. The total amount of DNA was kept constant by adding the appropriate amount of pUC19 vector to the transfection mixtures. Transfections were performed by the Calcium phosphate-MBS method (Stratagene, La Jolla, CA) according to the manufacturer's instructions.
5637 Transfections were performed essentially as described above except the DNA mixes contained 1 mg (®xed plasmid concentrations) or 0 ± 1 mg (plasmid titrations) of pCMV-RB vector, 1 mg of pE2-CAT reporter plasmid and 1 mg pCMV-b-gal. The lipofectin reagent (Gibco, Bethesda, MD) was used with a 3 : 1 ratio of lipid : DNA. Cells were harvested 48 h after transfection, lysates were prepared and CAT assays were performed as described (Gorman et al., 1982) . TLC plates were visualized on a phosphorimager SF (Molecular Dynamics, Sunnyvale, CA) and percent conversion was calculated using ImageQuant 3.3 software. CAT activities were normalized for variations in transfection eciency according to the b-galactosidase activity (Rosenthal, 1987) of each sample.
Analysis of RB protein in transfected cells
RB protein in transfected cells was quantitatively and qualitatively analysed by resolution on SDS-polyacrylamide gels followed by Western blotting. To detect hyperphosphorylated species of p110 RB or p56 RB , transfected cells harvested from 6-well plates and were immediately resuspended and boiled in 100 uL of SDS sample buer (50 mM Tris-Cl, pH 6.8, 2% b-mercaptoethanol, 4% SDS, 0.2% bromophenol blue, 20% glycerol). Samples were electrophoresed for 2 ± 4 h at 20 mA on a discontinuous 16620 cm polyacrylamide-SDS gel system (Laemmli, 1970) consisting of a stacking gel (3% polyacrylamide, 37 : 1 acrylamide : bis-acrylamide) and resolving gel (6% polyacrylamide for p110 RB , 8% polyacrylamide for p56 RB ). Use of the discontinuous gel system as well as longer (415 cm) plates was necessary to achieve optimal resolution of hyperphosphorylated species of pRB. RB protein expressed in cells used for promoter repression assays was analysed by lysing cells in CAT lysis buer as described above. Total protein concentration in each lysate was determined by the micro protein assay kit (Biorad, Hercules, CA) and lysates containing equivalent amounts of total protein were then boiled in *20 mL of 16SDS sample buer. Lysates containing RB proteins were then resolved on 8 ± 16% gradient polyacrylamide gels (Novex, San Diego, CA). Electrophoresis was for 80 min at 160V.
Resolved RB proteins were transferred to Immobilon membranes (Millipore, Bedford, MA) and were incubated with a 1 : 2000 dilution of 3C8 monoclonal antibody (Wen et al., 1994) followed by incubation in 1 : 2000 goat anti-mouse Flow cytometry 10 6 5637 cells were seeded on 10 cm plates and allowed to adhere overnight. Cells were transfected as described above, except each transfection contained 5 mg pCMV-RB plasmid and 5 mg pCMV-CD20 (Zhu et al., 1994) . Forty-eight hours after transfection, cells were collected and cell cycle analysis was performed as described previously (Zhu et al., 1993) . Samples were analysed on a FACS-Scan (Becton-Dickenson). A minimum of 10, 000 CD20+ events was used for each cell cycle analysis. The percentage of cells in each phase of the cell cycle was determined using Mod®tLT software (San Diego, CA).
